RFC
PRTK

Russell Frank Company’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Russell Frank Company’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,100
Closed -$20K – 3060
2015
Q4 		$20K Sell
1,100
-100
-8% -$1.91K ﹤0.01% 2949
2015
Q3 		$23K Sell
1,200
-100
-8% -$2.49K ﹤0.01% 2956
2015
Q2 		$34K Buy
+1,300
New +$36.9K ﹤0.01% 2986
2013
Q4 		– Sell
-200
Closed -$8K – 3123
2013
Q3 		$8K Buy
200
+194
+3,233% +$6.95K ﹤0.01% 3295
2013
Q2 		$0 Buy
+6
New +$257 ﹤0.01% 3373

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Frank Company's PRTK Position: Q1 2016 in Review

Russell Frank Company sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2016, closing a stake of 1,100 shares — an estimated $20K sold.

Russell Frank Company first reported a position in PRTK in Q2 2013 and held it in 5 quarters. The position peaked at $34K in Q2 2015. 62 funds tracked by Wall St. Rank hold PRTK as of Q1 2016.

  • Russell Frank Company reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Russell Frank Company sold 1,100 Paratek Pharmaceuticals, Inc. shares in Q1 2016, an estimated $20K.
  • Russell Frank Company first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
  • Russell Frank Company's Paratek Pharmaceuticals, Inc. position peaked at $34K in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.